European Vaccines Landscape 2026: Biodefence, mRNA, Allergen, Infectious Disease

Denmark concentrates the European biodefence vaccine anchor through Bavarian Nordic (Kvistgaard). The MVA-BN platform holds regulatory approval for smallpox and monkeypox use in the US (JYNNEOS), EU (IMVANEX), and Canada (IMVAMUNE), and serves as the biodefence backbone for government stockpiling programmes. Bavarian Nordic also operates next-generation biodefence + travel-vaccine platforms and post-pandemic-era public-health programmes. Statens Serum Institut (Copenhagen) runs as Denmark’s national public-health reference lab and vaccine-related infrastructure, coordinating infectious-disease surveillance, reference laboratory services, and vaccine-preparedness workflows with the Danish Medicines Agency. For sponsors running biodefence or public-health vaccine programmes in Europe, Bavarian Nordic is the primary directory anchor and SSI is the reference-lab partner.

Valneva Sweden (Stockholm) operates as the European infectious-disease vaccine manufacturer with commercial products in travel + routine vaccination (IXIARO Japanese encephalitis, DUKORAL cholera, IXCHIQ chikungunya, plus a pipeline across Lyme disease and beyond). Rokote Laboratories Finland (Kuopio) develops nasal adenoviral-vector vaccines for COVID-19 and respiratory programmes at Phase 1 clinical scope. Synthaverse (Lublin, Poland) runs pharmaceutical + vaccine manufacturing as a Polish domestic operator. Germany adds IDT Biologika (Dessau-Rosslau) which operates viral vaccines + cell-and-gene-therapy + fill-finish CDMO at commercial scale. For sponsors running infectious-disease vaccine programmes, these four operators cover the directory-visible European manufacturing + development layer.

ALK-Abelló (Horsholm, Denmark) operates European allergen immunotherapy manufacturing at commercial scale, with standardised allergen-vaccine products for house dust mite, grass pollen, and related allergens. Desentum (Espoo, Finland) develops peptide-based allergen immunotherapy as a next-generation platform for clinical-stage allergy treatment. IO Biotech (Copenhagen, Denmark) runs immune-modulating vaccines that sit between traditional immunotherapy and cancer-vaccine approaches. Combined with the tolerance-based cell therapy operators covered in the Cell & Gene Therapy Europe 2026 brief (PolTREG, TolerogenixX), this forms the European tolerance-and-allergen vaccine layer.

mRNA vaccines concentrate in the German innovation core with BioNTech (Mainz) and CureVac (Tübingen). BioNTech shifted to large-scale commercial mRNA vaccine manufacturing during the COVID era (Comirnaty / BNT162b2 with Pfizer) and now runs infectious-disease and oncology mRNA programmes across its pipeline. CureVac operates an RNA platform with translational and clinical-development activity. The European mRNA supply chain (AGC Biologics Heidelberg mRNA + pDNA CDMO, BioSpring Frankfurt oligonucleotide API, IDT Biologika viral vectors) supports this layer. For the full mRNA supply chain story, the European mRNA & Immunotherapy 2026 brief is the dedicated read.

Around the established anchors, the directory surfaces a clinical-stage vaccine and platform layer. Nykode Therapeutics (Oslo, formerly Vaccibody) operates a DNA-vaccine and immunotherapy platform. Abera Bioscience (Uppsala) develops nasal and OMV (outer membrane vesicle) vaccine platforms for infectious disease. MinervaX (Frederiksberg, Denmark) runs maternal immunisation programmes for Group B Streptococcus. ExpreS2ion Biotechnologies (Horsholm) provides protein-expression + vaccine R&D + antigen-production platforms (used by malaria-vaccine developers and others). Valo Therapeutics (Helsinki) runs oncolytic virus + vaccine-vector + cancer-immunotherapy programmes. Froceth (Vilnius) develops adipose-derived individualised cancer-immunotherapy ATMPs. Together with Bavarian Nordic + Valneva + ALK-Abelló + Rokote + Desentum, these nine operators cover the clinical-stage + platform European vaccine innovator layer.

Vaccine programmes need matching diagnostic capacity. The directory surfaces three operators with infectious-disease IVD scope sitting adjacent to the vaccine layer: altona Diagnostics (Hamburg, Germany, real-time PCR assays for global infectious-disease testing), ORGENTEC Diagnostika (Mainz, infectious-disease + autoimmune testing), and ArcDia International (Turku, Finland, automated near-patient infectious-disease IVD). Abacus Diagnostica (Turku) adds rapid PCR sample-to-answer systems for infectious-disease testing. For sponsors running vaccine clinical trials that need matched diagnostic endpoints, these four operators form the European infectious-disease IVD layer — see the European Diagnostics Landscape 2026 brief for the full diagnostics context.

European vaccine regulation runs through EMA centralised approval (Committee for Medicinal Products for Human Use + EMA Emergency Task Force for public-health emergencies). Biodefence stockpiling programmes run through HERA (Health Emergency Preparedness and Response Authority, established 2021). Clinical-trial authorisation runs under CTIS + the Clinical Trials Regulation. GMP compliance is mandatory for commercial manufacturing; GDP compliance covers cold chain and distribution (see the European Pharma Cold Chain & GDP Logistics 2026 brief). EU-internal biodefence funding is being restructured under the Biotech Act + Biotech & Biomanufacturing Hub strategy. The EU Biotech Regulation 2026 brief covers the wider regulatory context for vaccines + biologics + AI.